IL-33 modulates the immune response of several cells, including ILC2, Th2, and M2 macrophages, and can be derived from tumor cells, with the ability to recruit TGF-β, a cytokine that has pro-tumor activity by suppressing the activity of cytotoxic T cells (CTLs) [41]. The gene discussed is IL33; the disease is neoplasm.